Stocktoria
RIGEL PHARMACEUTICALS INC RIGL
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2000-11-29
RIGEL PHARMACEUTICALS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $294.3M | $179.3M | $116.9M | $120.2M | $149.2M |
| R&D expense | $33.3M | $23.4M | $24.5M | — | — |
| SG&A expense | $115.9M | $113.1M | $105.7M | $112.5M | $91.9M |
| Operating income | $125.5M | $24.2M | -$20.5M | -$55.5M | -$12.5M |
| Interest expense | — | $7.9M | $6.9M | $3.7M | $4.9M |
| Income tax | -$245.2M | $881,000 | $0 | — | $605,000 |
| Net income | $367.0M | $17.5M | -$25.1M | -$58.6M | -$17.9M |
| EPS (diluted) | $19.48 | $0.99 | $-1.44 | $-3.44 | $-0.11 |
| Operating cash flow | $75.7M | $31.5M | -$5.7M | -$73.8M | $5.9M |
| Free cash flow | — | — | — | -$74.2M | $5.3M |
| Cash & equivalents | $40.6M | $56.7M | $32.8M | $24.5M | $18.9M |
| Inventory | $11.5M | $6.0M | $5.5M | $9.1M | $6.6M |
| Total assets | $513.6M | $164.0M | $117.2M | $134.3M | $167.3M |
| Total liabilities | $122.1M | $160.7M | $145.9M | $147.9M | $137.0M |
| Shareholders' equity | $391.5M | $3.3M | -$28.6M | -$13.6M | $30.4M |
Source: SEC EDGAR filings · CIK 0001034842 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.